Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer

NCT07283835 is registered in ClinicalTrials.gov with Lepu Biopharma Co., Ltd. as lead sponsor.

NCT NCT07283835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07283835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer
Lead sponsor
Lepu Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
December 31, 2028
Enrollment
16 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade ta/ t1 papillary disease bladder cancer, non muscle invasive bladder cancer